Tirzepatide – BiotechReality – Information Intelligence System for Biopharma

Quick Summary Eli Lilly receives FDA approval for Zepbound KwikPen multi-dose device. Four-dose pen delivers one month's supply in a single device. Available through LillyDirect at identical pricing to single-dose vials. Zepbound is the #1 prescribed injectable obesity medication in 2025. Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen device. This regulatory milestone comes as Zepbound solidifies its position as the number one prescribed injectable obesity management medication in the United States. Eli Lilly Expands Treatment Options with New KwikPen Device The new KwikPen device delivers a full month of treatment in a single convenient device, providing patients with an additional option beyond the currently available single-dose vials. Both delivery options are now available at the same self-pay price through LillyDirect, Eli Lilly's digital health platform, with pricing starting at $299 per month for the 2.5 mg dose. Zepbound is the #1 prescribed injectable obesity-management medication, helping adults achieve meaningful and clinically proven weight loss, As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines. Ilya Yuffa Read More: Lilly to Offer All Approved Doses of Zepbound (tirzepatide) in Single-Dose Vials Through LillyDirect Unprecedented Patient Access Through LillyDirect Platform The demand for Zepbound reflects a significant shift in how patients access obesity treatments. Through LillyDirect, Eli Lilly's comprehensive digital health platform, patients have gained unprecedented access to affordable weight management solutions at self-pay prices offering 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity. In 2025, over one million patients accessed Lilly treatments through LillyDirect. Most remarkably, one out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials during this period, demonstrating strong patient demand for this innovative access model. Clinical Efficacy: How Zepbound Delivers Exceptional Weight Loss Results The clinical evidence supporting Zepbound's position as the leading obesity medication is compelling. As a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, Zepbound tackles the underlying causes of excess weight by reducing appetite and food intake in ways that other single-mechanism medications cannot match. SURMOUNT-1 Trial Results In the landmark SURMOUNT-1 clinical trial, which evaluated Zepbound across 72 weeks, adults demonstrated sustained weight loss across all approved maintenance doses when combined with diet and exercise modifications. The trial demonstrated dose-dependent efficacy: Zepbound 5 mg: 15.0% average weight loss (approximately 34 pounds) Zepbound 10 mg: 19.5% average weight loss (approximately 44 pounds) Zepbound 15 mg: 20.9% average weight loss (approximately 48 pounds) Placebo: 3.1% average weight loss (approximately 7 pounds) Average baseline weights were relatively consistent across treatment groups, ranging from 226.8 to 233.3 pounds for active treatment arms and 231.0 pounds for placebo. Read More: Zepbound Demonstrates Superior Weight Loss Over Wegovy in Head-to-Head Study – SURMOUNT-5 Phase 3b Clinical Trial Results SURMOUNT-5 Comparative Trial: Zepbound vs. Wegovy The SURMOUNT-5 study provided direct head-to-head comparison data between Zepbound and injectable Wegovy (semaglutide), demonstrating Zepbound's superior efficacy. In this 72-week, open-label, Phase 3b trial of adults with obesity or overweight plus comorbidities (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), results showed: Zepbound at Maximum Tolerated Dose (10-15 mg): 20.2% average weight loss (approximately 50 pounds) Injectable Wegovy at Maximum Tolerated Dose (1.7-2.4 mg): 13.7% average weight loss (approximately 33 pounds) This 6.5 percentage point difference in weight loss represents a clinically meaningful advantage for Zepbound users, with patients losing approximately 17 more pounds on average compared to Wegovy. Comprehensive Indication Profile and FDA-Approved Uses Zepbound is indicated for two distinct clinical applications, representing the full scope of its FDA-approved therapeutic uses: Primary Indication: Chronic Weight Management Zepbound is approved for use in adults with obesity, as well as some adults with overweight who also have weight-related medical problems (comorbidities), to help lose excess body weight and maintain that weight loss. Available in doses of 2.5 mg (starting dose only), 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the medication provides flexibility for individualized dosing based on patient tolerance and response. Secondary Indication: Obstructive Sleep Apnea Management Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA symptoms. For this indication, the recommended maintenance doses are 10 mg or 15 mg administered subcutaneously once per week. Administration and Safety Parameters Zepbound is administered via subcutaneous injection once weekly, with patients able to inject into the stomach, thigh, or have a healthcare provider administer the injection into the upper arm. Patients are instructed to rotate injection sites with each weekly dose to minimize injection-site reactions. It is critical that Zepbound not be used concurrently with other tirzepatide-containing products or any other GLP-1 receptor agonist medicines. Safety and efficacy in pediatric populations have not been established. Information: Eli Lilly and Company Last Modified:

Tag: Tirzepatide

Zepbound (Tirzepatide) Receives FDA Approval for Multi-Dose KwikPen

Wegovy® Shows Superior Cardiovascular Protection Over Tirzepatide in Real-World Study

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment